


Preliminary Program



International Parkinson and
Movement Disorder Society

**International Congress of Parkinson's
Disease and Movement Disorders®**

NICE, FRANCE SEPTEMBER 22-26, 2019

Table of Contents

About MDS.....	1
Purpose, Mission and Goals.....	1
MDS Officers (2017-2019).....	1
MDS International Executive Committee.....	2
International Congress Oversight Committee.....	2
Congress Local Organizing Committee	2
Congress Scientific Program Committee	2
Past-Presidents	2
International Medical Society For Motor Disturbances Past-Presidents.....	2
MDS International Secretariat.....	2
International Congress Information	3
Abstract Poster Information.....	3
Exhibition	3
Official Language.....	3
Photography Policy.....	3
Registration	3
Special Accessibility Needs.....	3
Venue	3
International Congress Events	4
International Congress Schedule-at-a-Glance	5
International Congress Session Definitions.....	6
Scientific Program.....	7
Sunday, September 22, 2019	7
Monday, September 23, 2019	8
Tuesday, September 24, 2019	12
Wednesday, September 25, 2019.....	16
Thursday, September 26, 2019	20
Non-CME Educational Activities	21
Faculty Listing.....	22
CME Information	25
Acknowledgements	26

About MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

Purpose, Mission and Goals

Purpose:

The objective and mission of the Society shall be to advance the neurological sciences pertaining to movement disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:

To disseminate knowledge about movement disorders by:

- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about movement disorders
- Sponsoring International Congresses and symposia on movement disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of movement disorders by:

- Using the Society's influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with movement disorders, the Society will provide expertise, advice and guidance to:

- Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- The public (media) and patient support groups by informing them of new research and therapeutic advances
- Governments to assist them in the development of policies that affect support of research and patient care
- Educational efforts to assist in developing standards of training in the specialty

MDS Officers (2017-2019)



President
Christopher Goetz, *USA*



Secretary
Susan Fox, *Canada*



Treasurer
Victor Fung, *Australia*



Past-President
Oscar Gershanik, *Argentina*



President-Elect
Claudia Trenkwalder, *Germany*



Secretary-Elect
Bastiaan Bloem, *Netherlands*



Treasurer-Elect
Louis Tan, *Singapore*

About MDS

MDS International Executive Committee

Charles Adler, *USA*
Daniela Berg, *Germany*
Shengdi Chen, *People's Republic of China*
Carlos Cosentino, *Peru*
Joaquim Ferreira, *Portugal*
Jeffrey Kordower, *USA*
Mayela Rodriguez Violante, *Mexico*
D. James Surmeier, *USA*
Pille Taba, *Estonia*
Ryosuke Takahashi, *Japan*

International Congress Oversight Committee

Chair: Matthew Stern, *USA*
Jean-Christophe Corvol, *France*
Günther Deuschl, *Germany*
Victor Fung, *Australia*
Oscar Gershanik, *Argentina*
Christopher Goetz, *USA*
Hyder Jinnah, *USA*
Claudia Trenkwalder, *Germany*

Congress Local Organizing Committee

Chair: Jean-Christophe Corvol
Philippe Damier
Luc Defebvre
Franck Durif
Alexandra Durr
Caroline Giordana
Wassilios Meissner
Elena Moro
Olivier Rascol
Christine Tranchant
Marie Vidailhet

Congress Scientific Program Committee

Chair: Hyder Jinnah, *USA*
Co-Chair: Jean-Christophe Corvol, *France*
Roongroj Bhidayasiri, *Thailand*
Vincenzo Bonifati, *Netherlands*
M. Angela Cenci Nilsson, *Sweden*
Shengdi Chen, *People's Republic of China*
Steven Frucht, *USA*
Emilia Gatto, *Argentina*
Christopher Goetz, *USA*
Jennifer Goldman, *USA*
Etienne Hirsch, *France*
Roland Dominic Jamora, *Philippines*
Beomseok Jeon, *South Korea*
Han-Joon Kim, *South Korea*
Vladimir Kostic, *Serbia*
Shen-Yang Lim, *Malaysia*
Irene Litvan, *USA*
Karen Marder, *USA*
Wassilios Meissner, *France*
Vincent Mok, *Hong Kong*
Elena Moro, *France*
Alice Nieuwboer, *Belgium*
Maria Stamelou, *Greece*
Matthew Stern, *USA*
Antonio Strafella, *Canada*
Carolyn Sue, *Australia*
Ryosuke Takahashi, *Japan*
Helio Teive, *Brazil*
Claudia Trenkwalder, *Germany*

Past-Presidents

2015-2017 Oscar Gershanik, *Argentina*
2013-2015 Matthew Stern, *USA*
2011-2013 Günther Deuschl, *Germany*
2009-2011 Philip Thompson, *Australia*
2007-2009 Anthony Lang, *Canada*
2005-2006 Andrew Lees, *United Kingdom*
2003-2004 C. Warren Olanow, *USA*
2001-2002 Werner Poewe, *Austria*
1999-2000 Mark Hallett, *USA*
1997-1998 Eduardo Tolosa, *Spain*
1995-1996 Joseph Jankovic, *USA*
1991-1994 C. David Marsden, *United Kingdom*
1988-1991 Stanley Fahn, *USA*

International Medical Society For Motor Disturbances Past-Presidents

1993-1994 C. Warren Olanow, *USA*
1991-1992 Bastian Conrad, *Germany*
1989-1990 Mark Hallett, *USA*
1987-1988 Mario Manfredi, *Italy*
1985-1986 C. David Marsden, *United Kingdom*

MDS International Secretariat

International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org
Website: www.movementdisorders.org

International Congress Information

Abstract Poster Information

Poster Sessions will be featured from Monday through Wednesday of the International Congress to ensure delegates are given the opportunity to review as many abstracts as possible. Please visit www.mdscongress.org/Congress/Program--Abstracts.htm for further details and information about Abstracts for the 2019 International Congress.

Exhibition

Manufacturers, distributors and suppliers of products and services for physicians and researchers involved with Movement Disorders are invited to participate in the International Congress exhibition. To receive a copy of the Support Opportunities and Exhibitor Prospectus, please contact the MDS International Secretariat at congress@movementdisorders.org or visit www.mdscongress.org/Congress/Sponsorship--Exhibiting/Prospectus.htm. The exhibition is open to all registered delegates.

Official Language

The official language of the 2019 International Congress is English.

Photography Policy

Photography is not permitted in any of the 2019 International Congress scientific and/or educational sessions or in the poster areas.

Registration

Please visit www.mdscongress.org/Congress/Registration.htm for details and to register online.

The International Congress registration fee includes admission to all scientific sessions, Exhibit Hall and Poster Hall and entrance to the Welcome Ceremony and MDS Video Challenge as well as delegate material, a Final Program, the abstracts on USB, a daily morning coffee break and a daily lunch. The registration fee excludes travel and accommodations.

Registration Cancellation/Refund Policy

All cancellations must be requested in writing.

- Up to August 22, 2019 (Final pre-registration deadline): 100% refund, minus a \$75 administrative charge
- From August 23 – September 12, 2019: 50% refund
- From September 13, 2019 onward: No refund

Registration Desk

Name badge, scientific session tickets, Final Program and USB with full abstract list can be collected at the International Congress Registration desk in Agora 1 during the following hours**:

Saturday, September 21:	16:00 – 20:00
Sunday, September 22:	7:00 – 20:00
Monday, September 23:	7:00 – 18:00
Tuesday, September 24:	7:00 – 18:00
Wednesday, September 25:	7:00 – 18:00
Thursday, September 26:	7:00 – 12:00

**Please note that these hours are subject to change.

Special Accessibility Needs

Delegates requiring special arrangements in order to fully participate in the International Congress should provide a written description of such needs on their registration form or send an e-mail to congress@movementdisorders.org. To ensure appropriate accommodations, all special needs should be addressed in advance with the MDS International Secretariat.

Venue

Nice Acropolis Convention Centre
1 Esplanade Kennedy 06364
Nice Cedex 4
France

International Congress Events

Saturday, September 21, 2019



NEW! Movement Disorders Awareness 5k Run/Walk: Nice en Mouvement

Join MDS for a Movement Disorders Awareness 5k run/walk at the Promenade des Anglais in Nice, Saturday, September 21, 2019 at 18:00

to benefit La Société Francophone des Mouvements Anormaux (SOFMA). All participants receive a t-shirt and light refreshments at the finish line. If you are interested in participating, you may sign up during the International Congress registration process. Space is limited to 300 delegates, so be sure to register early.

Please note that there is an additional fee for this event.

If you do not plan to run or walk, please consider lining up along the event route to cheer on your colleagues.

The Movement Disorders Awareness 5k Run/Walk is sponsored by Boston Scientific.

Sunday, September 22, 2019

Welcome Ceremony

19:30 – 21:30

All International Congress delegates are warmly invited to attend the International Congress Welcome Ceremony. This event is open to all registered delegates.

Tuesday, September 24, 2019

Young Delegates Networking Event

19:30 – 21:30

MDS invites all registered International Congress delegates to attend the Young Delegates Networking Event. This event will provide an excellent opportunity for delegates who are in the beginning phase of their career to network and socialize with other up-and-coming experts in the field.

The Young Delegates Networking Event is sponsored by Acorda Therapeutics and Medtronic.

Wednesday, September 25, 2019

MDS Video Challenge

19:00 – 22:00

Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by the Panel of Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for delegates to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

The Panel of Experts:

Stewart Factor, USA

Manju Kurian, United Kingdom

Tiago Mestre, Canada

Francesca Morgante, United Kingdom

Martin Paucar Arce, Sweden

This event is open to all registered delegates. For more information about the MDS Video Challenge, please contact The MDS International Secretariat at congress@movementdisorders.org.

The MDS Video Challenge is sponsored by Boston Scientific.

International Congress Schedule-at-a-Glance

	Sunday, September 22		Monday, September 23		Tuesday, September 24		Wednesday, September 25		Thursday, September 26	
8:00	Therapeutic Plenary Session 8:00 - 10:00		Plenary Session (Presidential Lectures) 8:00 - 10:00		Plenary Session 8:00 - 9:30		Plenary Session 8:00 - 9:30		Plenary Session 8:00 - 9:30	
8:30										
9:00										
9:30										
10:00	MDS Regional Assemblies 10:00 - 11:00		Break 10:00 - 10:30		Break 9:30 - 10:30	MDS Business Meeting 9:30 - 10:30	Break 9:30 - 10:00		Break 9:30 - 10:00	
10:30										
11:00	Therapeutic Plenary Session 11:00 - 13:00		Plenary Session 10:30 - 12:30		Plenary Session (Grand Rounds) 10:30 - 12:30		Plenary Session 10:00 - 12:00		Plenary Session (Controversies) 10:00 - 11:00	
11:30										
12:00										
12:30										
13:00	Break 13:00 - 14:30		Corporate Therapeutic Symposia 12:45 - 13:45		Corporate Therapeutic Symposia 12:45 - 13:45		Corporate Therapeutic Symposia 12:15 - 13:15		End	
13:30										
14:00										
14:30										
15:00	Therapeutic Plenary Session 14:30 - 16:30		Poster Sessions & Guided Poster Tours 13:45 - 15:15		Poster Sessions & Guided Poster Tours 13:45 - 15:15		Poster Sessions & Guided Poster Tours 13:15 - 14:45		Break 14:45 - 15:00	
15:30										
16:00										
16:30										
17:00	Break 16:30 - 17:00		Parallel Sessions & Teaching Courses 15:30 - 17:30		Science of Industry Session (non-CME) 15:30 - 17:30		Parallel Sessions & Teaching Courses 15:00 - 17:00		Break 17:00 - 17:30	
17:30										
18:00										
18:30										
19:00	Therapeutic Plenary Session 17:00 - 19:00		Break 17:30 - 18:00		Break 17:30 - 18:00		Skills Workshops, Video Sessions, Special Topic Sessions 17:30 - 19:00		Break 17:00 - 17:30	
19:30										
20:00										
20:30										
21:00	Welcome Ceremony 19:30 - 21:30				Young Delegates Networking Event 19:30 - 21:30		MDS Video Challenge 19:00 - 22:00			
21:30										
22:00										

Legend:


- CME Accredited Sessions
- Non-CME Educational Activities
- Corporate Therapeutic Symposia (non-CME)
- MDS Activities
- Events
- Breaks

Legend:

- CME Accredited Sessions
- Non-CME Educational Activities
- Corporate Therapeutic Symposia (non-CME)
- MDS Activities
- Events
- Breaks

International Congress Session Definitions

CME Accredited Sessions

2019 International Congress Themed Sessions: At each annual International Congress, the Congress Scientific Program Committee (CSPC) selects a theme that is highlighted throughout the meeting. This year's theme, *Translating the Science of Movement Disorders into Clinical Practice*, will be showcased with international experts serving as faculty. Delegates can elect to attend any or all of these sessions. Themed sessions are designated in the program with .

Controversies: This Plenary Session is designed to involve all International Congress delegates. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected "hot" topics will be open for debate among the panelists.

Grand Rounds: In this interactive session, MDS experts will examine both common and rare movement disorder patients. The audience will learn how they formulate diagnoses and manage these interesting and challenging patients.

Parallel Sessions: These concurrent sessions provide an in-depth summary of new clinical and basic research findings, state-of-the-art treatment options, and future strategies on a variety of focused topics within the field of Movement Disorders.

Plenary Sessions: These sessions provide an overview of the latest clinical and basic science research findings and state-of-the-art information relating to topics of broad interest within the field of Movement Disorders.

Skills Workshops: These concurrent sessions provide practical illustrations of clinical or scientific techniques relevant to the field of Movement Disorders through video examples and equipment demonstrations.

NEW! Special Topics in Movement Disorders: These interactive sessions address "hot" topics in science or medicine using a variety of different formats that may include lectures, video presentations, and audience interaction.

Teaching Courses: These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides.

Therapeutic Plenary Sessions: These sessions provide an overview of the latest, state-of-the-art treatment options in the diagnosis and management of Parkinson's disease and other movement disorders.

Video Sessions: These concurrent sessions focus on video demonstrations to provide an overview of clinical movement disorders.

Corporate Therapeutic Symposia (non-CME)

These company-based informational sessions provide delegates with non-CME educational opportunities to learn the latest in therapeutics.

Non-CME Accredited Educational Activities

Guided Poster Tours: Guided Poster Tours give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several different topics.

Poster Sessions: Poster sessions give each delegate an opportunity to view their colleagues' posters on the most current research in the field of Movement Disorders. Posters are available for daily viewing and authors are present for 90 minutes to discuss their work and answer questions.

NEW! Science of Industry Session: These interactive sessions will provide delegates with a non-CME educational (non-CME) opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

International Congress Events

MDS Video Challenge: The goal of this session is for delegates to learn from a series of unusual patients and observe how senior experts approach a challenging case. A world-renowned panel of Movement Disorders experts guide delegates through unique Movement Disorder cases as they are presented by representatives from Movement Disorder centers around the world.

Welcome Ceremony: All International Congress delegates are warmly invited to attend the Welcome Ceremony at the Nice Acropolis Convention and Exhibition Centre. This event is open to all registered delegates and there is no additional fee to attend.

Young Delegates Networking Event: MDS invites all registered International Congress delegates to attend the Young Delegates Networking Event. This event will provide an excellent opportunity for delegates who are in the beginning phase of their career to network and socialize with other up-and-coming experts in the field.

MDS Activities

MDS Business Meeting: Open to all International Congress delegates, the Society encourages Members to attend the MDS Business Meeting to receive updates from the MDS President and other MDS Officers on the Society, the various Regional Sections, to participate in the Officers' and International Executive Committee (IEC) election and to discuss other Society concerns.

Regional Assemblies: Delegates from each of the various MDS Regional Sections (MDS-AOS, MDS-ES, MDS-PAS, and Africa) are invited to participate in the Regional Assemblies to receive updates on activities and general concerns from within the sections.

International Congress Faculty Roles

Chair: Facilitates the learnings of the session; ensures that learning objectives are met during the presentation(s), and engages the learners as needed.

CSPC Liaison: Develops the session from the onset and provides guidance to ensure that the overall objectives are met.

Speaker / Presenter: Creates and delivers the presentation materials, and participates in the dialogue of the session.

Sunday, September 22, 2019

1101 Therapeutic Plenary Session

Recognition and Treatment of Early Stage Parkinson's Disease

8:00 – 10:00

Chairs: Franck Durif, *France*
Susan Fox, *Canada*

Distinguishing Prodromal and Early Parkinson's Disease
Daniela Berg, *Germany*

Treatment of Early Parkinson's Disease
Shen-Yang Lim, *Malaysia*

Disease Modifying Treatment for Parkinson's Disease:
Current and Future
Olivier Rascol, *France*

CSPC Liaison: Shengdi Chen, *People's Republic of China*

At the conclusion of this session, participants should be better able to:

1. Discuss the concept of prodromal Parkinson's disease and its evolution to Parkinson's disease
2. Summarize the non-pharmacological and pharmacologic treatment of early stage Parkinson's disease
3. Review the history and the future of disease modifying treatment for Parkinson's disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

1102 Therapeutic Plenary Session

Recognition and Treatment of Complications in Later Stage Parkinson's Disease

11:00 – 13:00

Chairs: Elena Moro, *France*
Louis Tan, *Singapore*

Motor and Non-Motor Fluctuations and Dyskinesias
Angelo Antonini, *Italy*

Cognitive, Behavioral and Psychiatric Problems
Jennifer Goldman, *USA*

Gait, Balance and Falls
Nir Giladi, *Israel*

CSPC Liaison: Han-Joon Kim, *South Korea*

At the conclusion of this session, participants should be better able to:

1. Illustrate the phenomenology and treatment of the motor and non-motor fluctuations and dyskinesias in later stage Parkinson's disease
2. Review cognitive, behavioral and psychiatric problems and their treatment in later stages of Parkinson's disease
3. Identify common axial problems affecting gait and balance, and their treatment in later stages of Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

1103 Therapeutic Plenary Session

Diagnosis and Treatment of Atypical Parkinsonian Disorders

14:30 – 16:30

Chairs: Irene Litvan, *USA*
Francois Tison, *France*

Clinical Manifestations of Atypical Parkinsonian Disorders
Irene Litvan, *USA*

Ancillary Investigations for the Diagnosis of Atypical Parkinsonian Disorders
Maria Teresa Pellecchia, *Italy*

Therapeutic Options for Atypical Parkinsonian Disorders
Gregor Wenning, *Austria*

CSPC Liaison: Wassilios Meissner, *France*

At the conclusion of this session, participants should be better able to:

1. Distinguish atypical parkinsonian disorders based on clinical features
2. Discuss ancillary investigations for the diagnosis of atypical parkinsonian disorders
3. Review therapeutic options for atypical parkinsonian disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

1104 Therapeutic Plenary Session

Recognition and Treatment of Dystonia, Tremor and Ataxia

17:00 – 19:00

Chairs: Antonio Strafella, *Canada*
Christine Tranchant, *France*

Therapeutic Options for Dystonia
Marie Vidailhet, *France*

Treatment Options for Tremor
Elan Louis, *USA*

Management of Ataxia
Elizabeth Slow, *Canada*

CSPC Liaison: Antonio Strafella, *Canada*

At the conclusion of this session, participants should be better able to:

1. Identify management strategies for dystonia
2. Select treatment options for tremor
3. Summarize managements options for ataxia

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2019 International Congress Theme

At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year's theme, *Translating the Science of Movement Disorders into Clinical Practice*, will be showcased in three Plenary Sessions, eleven (11) Parallel Sessions, one Skills Workshop, and one Special Topic Session. International experts will serve as faculty, and the meeting delegates can elect to attend any of these sessions.



Themed sessions



Recorded sessions



Ticketed sessions

Monday, September 23, 2019

2101 Plenary Session

Presidential Lectures

8:00 – 10:00

Chairs: Christopher Goetz, *USA*
Claudia Trenkwalder, *Germany*

Stanley Fahn Lecture
Cynthia Comella, *USA*

Junior Award Lectures
To Be Announced

C. David Marsden Lecture
Christine Klein, *Germany*

CSPC Liaison: Buz Jinnah, *USA*

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2102 Plenary Session

Update on Neurosurgical Interventions for Movement Disorders

10:30 – 12:30

Chairs: Jean-Philippe Azulay, *France*
Stéphane Palfi, *France*

Redefining Neurosurgical Indications and Interventions for Movement Disorders
Helen Bronte-Stewart, *USA*

Lessons Learned and Current Developments in Neuromodulation
Maria Fiorella Contarino, *Netherlands*

Overview on MRI-Focused Ultrasound
Clement Hamani, *Canada*

CSPC Liaison: Elena Moro, *France*

At the conclusion of this session, participants should be better able to:

1. Identify signs and appropriate surgical intervention for patients with movement disorders
2. Describe pros and cons of different neuromodulation treatments, including DBS
3. Summarize the latest available knowledge about MRI-focused ultrasound

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2203 Parallel Session

Cognitive Issues in Parkinson's Disease

15:30 – 17:30

Chairs: Bruno Dubois, *France*
Jennifer Goldman, *USA*

Cognitive Impairment: Clinical Phenotype and Heterogeneity
Caroline Williams-Gray, *United Kingdom*

Neuroimaging Markers of Cognitive Dysfunction
Antonio Strafella, *Canada*

Management Strategies for Cognitive Issues
Irena Rektorova, *Czech Republic*

CSPC Liaison: Jennifer Goldman, *USA*

At the conclusion of this session, participants should be better able to:

1. Illustrate the clinical phenotype and heterogeneity associated with cognitive issues in Parkinson's disease
2. Discuss neuroimaging markers associated with cognitive issues in Parkinson's disease
3. Review management strategies for cognitive issues in Parkinson's disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2204 Parallel Session

Parkinson's Disease and Atypical Parkinsonism: Tauopathies vs. Synucleinopathies

15:30 – 17:30

Chairs: Irene Litvan, *USA*
Maria Stamelou, *Greece*

Diagnostic Pearls in Recognizing Tauopathies vs. Synucleinopathies
Stephen Reich, *USA*

Pathophysiology and Targets for Therapeutic Interventions
Lawrence Golbe, *USA*

Disease Modifying Therapies
Huw Morris, *United Kingdom*

CSPC Liaison: Irene Litvan, *USA*

At the conclusion of this session, participants should be better able to:

1. Describe how to distinguish patients with tauopathies from synucleinopathies
2. Summarize the mechanisms leading to the development and spread of tauopathies versus synucleinopathies
3. Describe the biological rationale for experimental therapies

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2205 Science of Industry Session (non-CME)

See page 21 for complete session information.

Monday, September 23, 2019

2206 Parallel Session

Ataxia

15:30 – 17:30

Chairs: Alexandra Durr, *France*
Helio Teive, *Brazil*

The Clinical Approach to Patients with Ataxia
Hidehiro Mizusawa, *Japan*

From Phenotype to Genotype in Ataxia
Alexandra Durr, *France*

Ataxia Syndromes in Children and Adults
Ludger Schöels, *Germany*

CSPC Liaison: Buz Jinnah, *USA*

At the conclusion of this session, participants should be better able to:

1. Describe the approach for reaching an etiological diagnosis in patients with ataxia
2. Examine the different phenotypes of ataxia in both children and adults
3. Describe the genetic basis for common disorders with ataxia

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees



This presentation is offered in collaboration with the European Academy of Neurology.

2207 Parallel Session

Tics and Tourette Syndrome: From Bench to Bedside

15:30 – 17:30

Chairs: Andreas Hartmann, *France*
Davide Martino, *Canada*

Motor and Behavioral Spectrum of Tics and Tourette Syndrome
Christos Ganos, *Germany*

Pathophysiology of Tics and Tourette Syndrome
Yulia Worbe, *France*

Pharmacological and Non-Pharmacological Therapy of Tics and Tourette Syndrome
Davide Martino, *Canada*

CSPC Liaison: Jean-Christophe Corvol, *France*

At the conclusion of this session, participants should be better able to:

1. Recognize the clinical spectrum (motor and behavioral) of tics and Tourette syndrome
2. Analyze the pathophysiology of tics and Tourette syndrome including both proposed sites of origin and abnormalities of synaptic transmission
3. Adapt the therapeutic approaches tailored to the needs of individual patients with tics and Tourette syndrome

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2208 Parallel Session

Translating the Science of Functional (Psychogenic) Movement Disorders Into Clinical Practice

15:30 – 17:30

Chairs: Beomseok Jeon, *South Korea*
Kathrin LaFaver, *USA*

Connecting Pathophysiology and Risk Factors to Clinical Care in Functional Movement Disorders
Selma Aybek Rusca, *Switzerland*

Treatment Choices in Functional Movement Disorders: Established and Novel Treatments
Kathrin LaFaver, *USA*

Putting It Together: How to Develop and Run a Clinical Service for Functional Movement Disorders
Mark Edwards, *United Kingdom*

CSPC Liaison: Beomseok Jeon, *South Korea*

At the conclusion of this session, participants should be better able to:

1. Explain the pathophysiology and risk factors of functional movement disorders
2. Discuss the evidence base for physiotherapy and multidisciplinary rehabilitation in functional movement disorders
3. Discuss how to design care pathways and run a service for people with functional movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2309 Teaching Course

Integrated Management of Movement Disorders: The Example of Parkinson's Disease

15:30 – 17:30

Chairs: Alice Nieuwboer, *Belgium*
Mayela Rodriguez Violante, *Mexico*

How to Organize Multidisciplinary Care
Carsten Eggers, *Germany*

Physical and Occupational and Speech Therapy
Alice Nieuwboer, *Belgium*

Shifting Management Towards Patient-Centered Care and Empowerment
Maria Piemonte, *Brazil*

CSPC Liaison: Wassilios Meissner, *France*

At the conclusion of this session, participants should be better able to:

1. Describe the organization of a multidisciplinary care team for Parkinson's disease
2. Apply the evidence for physical, occupational and speech therapy for Parkinson's disease
3. Discuss strategies to enhance patient-centered care and patient empowerment in patients with Parkinson's disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.

Monday, September 23, 2019

2310 Teaching Course

Using Imaging Methods for Movement Disorders

15:30 – 17:30

Chairs: Han-Joon Kim, *South Korea*
Stephane Lehericy, *France*

Structural and Functional MRI Imaging
Stephane Lehericy, *France*

Brain Imaging Using PET and SPECT
Jee-Young Lee, *South Korea*

Other Novel and Non-CNS Imaging Techniques
Thilo Van Eimeren, *Germany*

CSPC Liaison: Han-Joon Kim, *South Korea*

At the conclusion of this session, participants should be better able to:

1. Explain the role of MRI techniques in the diagnosis of Parkinson's disease and other movement disorders
2. Discuss how PET and SPECT imaging can detect brain alterations in Parkinson's disease and other movement disorders
3. Report the use and limitations of other neuroimaging techniques in Parkinson's disease and other movement disorders (TCS, NIRS, OCT, and MIBG)

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

This course will be recorded and developed into an online MDS eLearning module that will be available to MDS Members.

2411 Skills Workshop

Advanced Therapies for Movement Disorders: Difficult Cases and Pitfalls

18:00 – 19:30

Tove Henriksen, *Denmark*
Andrea Kühn, *Germany*

CSPC Liaisons: Elena Moro, *France*
Claudia Trenkwalder, *Germany*

In this interactive session, the presenters will describe the selection process of parkinsonian patients who can benefit from advanced therapies, and how to recognize and manage issues and complications related to these treatments. In particular, cases presenting with infusion therapies such as apomorphine pump and levodopa intestinal infusion, and Deep Brain Stimulation therapy will be discussed.

At the conclusion of this session, participants should be better able to:

1. Describe the selection of patients for the different advanced therapies
2. Recognize and manage problems and side effects during infusion therapies with apomorphine and LDCD
3. Identify and manage the most frequent problems related to neuromodulation surgery and post-surgery management

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2412 Skills Workshop

Using Genetic Tools for Diagnosis

18:00 – 19:30

Hui Fang Shang, *People's Republic of China*
Matthis Synofzik, *Germany*

CSPC Liaison: Vincenzo Bonifati, *Netherlands*

In this interactive session, the presenters will describe the different tools currently available for the laboratory diagnosis of genetic movement disorders, including tools for the detection of mutations in single genes (including small sequence and copy number variants), as well as gene panels, clinical whole-exome (WES) and whole-genome sequencing (WGS).

At the conclusion of this session, participants should be better able to:

1. Identify currently existing tools for the laboratory diagnosis of genetic movement disorders
2. Recognize the advantages and disadvantages of the different tools
3. Define the strategy of choice for diagnostic genetic testing of patients with movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

2413 Skills Workshop

Metabolic Movement Disorders

18:00 – 19:30

Jennifer Friedman, *USA*
Mayela Rodriguez Violante, *Mexico*

CSPC Liaison: Maria Stamelou, *Greece*

In this interactive session, the presenters will discuss the phenotypic spectrum of movement disorders caused by a variety of metabolic diseases, diagnostic tools to approach metabolic movement disorders and available treatment plans for patients with these disorders.

At the conclusion of this session, participants should be better able to:

1. Interpret the phenotypic spectrum of movement disorders caused by metabolic diseases
2. Describe diagnostic tools for metabolic disease causing movement disorders
3. Design, review and modify a treatment plan for patients with metabolic movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Monday, September 23, 2019

2514 Video Session

Atypical Parkinsonism

18:00 – 19:30

Gesine Respondek, *Germany*

Iva Stankovic, *Serbia*

CSPC Liaison: Ryosuke Takahashi, *Japan*

In this interactive session, the presenters will explain the clinical diagnostic criteria and red flags for atypical parkinsonism and show videos of the phenomenology of patients with atypical parkinsonism such as progressive supranuclear palsy, corticobasal syndrome, multiple system atrophy and Lewy body disease. The audience will learn important tips to clinically distinguish atypical parkinsonism from Parkinson's disease.

At the conclusion of this session, participants should be better able to:

1. Identify the phenotypic spectrum of atypical parkinsonism
2. Describe clinical clues useful in the diagnosis of atypical parkinsonism
3. Explain current clinical diagnostic criteria of atypical parkinsonism

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2515 Video Session

A Case-Based Approach to Dystonia: What Would You Do?

18:00 – 19:30

Susan Bressman, *USA*

Joseph Jankovic, *USA*

CSPC Liaison: Steven Frucht, *USA*

In this interactive session, experienced movement disorders clinicians will use a case-based approach to describe the strategy for diagnosis and treatment of various types of dystonia, both common and rare.

At the conclusion of this session, participants should be better able to:

1. Recognize unusual presentations of various forms of dystonia
2. Explain the differences in opinion of applying modern practical techniques (oral medications, botulinum toxin, Deep Brain Stimulation, rehabilitation therapy) to treatment of a wide variety of forms of dystonia
3. Evaluate pitfalls in the diagnosis and treatment of dystonia

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2516 Special Topics in Movement Disorders

The Future Is Now: Telemedicine in Your Movement Disorders Practice

18:00 – 19:30

Esther Cubo Delgado, *Spain*

Ali Shalash, *Egypt*

CSPC Liaison: Maria Stamelou, *Greece*

In this interactive session, the presenters will discuss clinical situations in which telemedicine may be helpful for improving care of patients with movement disorders such as Parkinson's disease and will describe practical ways in which such telemedicine visits can be implemented in everyday clinical practice. The audience will observe and identify the challenges and possible hurdles that need to be overcome for telemedicine visits to be implemented in clinical practice.

At the conclusion of this session, participants should be better able to:

1. Detect situations amenable to telemedicine for improving patients' care
2. Describe ways in which a telemedicine visit can be implemented in clinical practice
3. Identify challenges in telemedicine visits and ways to overcome them

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2517 Special Topics in Movement Disorders

Gait Disorders: From Pathophysiology to the Clinic

18:00 – 19:30

Klaus Jahn, *Germany*

Jorik Nonnekens, *Netherlands*

CSPC Liaison: Alice Nieuwboer, *Belgium*

At the conclusion of this session, participants should be better able to:

1. Translate a systems understanding of gait disorder into the clinical picture
2. Recognize cerebellar and vestibular contributions to gait disorders and their management
3. Recognize corticostriatal dysfunction in gait disorders and their management

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

2518 Special Topics in Movement Disorders

Induced Pluripotent Stem Cells (iPS) and Organoids: State-of-the-Art

18:00 – 19:30

Agnete Kirkeby, *Denmark*

Wim Mandemakers, *Netherlands*

CSPC Liaison: Vincenzo Bonifati, *Netherlands*

In this session, the technology of induced pluripotent stem cells (iPS) and brain organoids as powerful tools for disease modeling will be presented, and the potential application of iPS in the experimental therapy of Parkinson's disease will be discussed.

At the conclusion of this session, participants should be better able to:

1. Illustrate the application of human induced pluripotent stem cell (iPS) technology and brain organoids to study mechanisms of movement disorders
2. Discuss the potential of human induced pluripotent stem cell (iPS) technology to treat Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Tuesday, September 24, 2019

3101 Plenary Session

Tremor Disorders: Challenges and Future Directions

8:00 – 9:30

Chairs: Kailash Bhatia, *United Kingdom*
Maria Stamelou, *Greece*

Overview of the New Classification Scheme for Tremor
Rodger Elble, *USA*

What Do We Know About Etiologies?
Peter Bain, *United Kingdom*

Pathophysiology of Tremor: Is Pathophysiology Useful in Diagnosis and Classification?
Rick Helmich, *Netherlands*

CSPC Liaison: Maria Stamelou, *Greece*

At the conclusion of this session, participants should be better able to:

1. Apply the new tremor classification scheme in everyday clinical practice
2. Describe how the etiologies of tremor relate to classification
3. Describe how the pathophysiology of tremor relates to the diagnosis and classification of tremor

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3102 Plenary Session

Grand Rounds

10:30 – 12:30

MDS Experts:

Tim Anderson, *New Zealand*
Mathieu Anheim, *France*
Steven Frucht, *USA*
Timothy Lynch, *Ireland*

CSPC Liaison: Jean-Christophe Corvol, *France*

In this interactive session, MDS experts will examine both common and complex movement disorder patients. The audience will gain expert advice on how to formulate diagnoses and manage interesting and challenging patients.

At the conclusion of this session, participants should be better able to:

1. Identify how experts use the clinical history and exam to formulate a diagnosis in movement disorder cases
2. Identify how experts use diagnostic testing in the differential diagnosis of movement disorders
3. Identify how experts plan therapies for movement disorder patients

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3203 Parallel Session

Psychosis and Hallucinations in Lewy Body Disorders

15:30 – 17:30

Chairs: Gilles Fenelon, *France*
Simon Lewis, *Australia*

Current Theories on Visual Hallucinations
Nico Diederich, *Luxembourg*

Neuroimaging and Visual Hallucinations: A Window Into Their Mechanism
Simon Lewis, *Australia*

Management Strategies for Visual Hallucinations and Psychosis
Laura Marsh, *USA*

CSPC Liaison: Jennifer Goldman, *USA*

At the conclusion of this session, participants should be better able to:

1. Identify current theories of visual hallucinations in Parkinson's disease and Lewy body disorders
2. Describe neuroimaging findings associated with visual hallucinations in Parkinson's disease and Lewy body disorders
3. Review management strategies for hallucinations and delusions in Parkinson's disease and Lewy body disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3204 Parallel Session

Challenges in Clinicogenetic Correlations: One Gene - Many Phenotypes; One Phenotype - Many Genes

15:30 – 17:30

Chairs: Vincenzo Bonifati, *Netherlands*
Enza Maria Valente, *Italy*

One Gene – Many Phenotypes
Niccolo Mencacci, *USA*

One Phenotype – Many Genes
Aurelie Meneret, *France*

Clinical Implications – Diagnosis and Management Strategies
Enza Maria Valente, *Italy*

CSPC Liaison: Vincenzo Bonifati, *Netherlands*

At the conclusion of this session, participants should be better able to:

1. Recognize the sometimes different and complex phenotypes of monogenic mutations
2. Describe similar clinical phenotypes resulting from mutations in different genes
3. Discuss the evolving role of genetics in the diagnosis and management of movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

Tuesday, September 24, 2019

3205 Parallel Session

Myoclonus

15:30 – 17:30

Chairs: Marina De Koning-Tijssen, *Netherlands*
Steven Frucht, *USA*

The Essential Role of Physiology in Understanding and
Evaluating Myoclonus
Hiroshi Shibasaki, *Japan*

The Progressive Myoclonic Epilepsies - How Genetics Have
Revolutionized Understanding of These Disorders
Pierre Genton, *France*

Treatment of Myoclonus: What Is the Evidence?
Martje Van Egmond, *Netherlands*

CSPC Liaison: Steven Frucht, *USA*

At the conclusion of this session, participants should be better able to:

1. Explain the role of physiology in the evaluation and management of myoclonus
2. Appreciate the enormous strides made in understanding genetic forms of myoclonus
3. Review the evidence supporting decisions on treatments for myoclonus

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals,
Practitioners, Students/Residents/Trainees

3206 Parallel Session

Translational Science of Dystonia

15:30 – 17:30

Chairs: William Dauer, *USA*
Marie Vidailhet, *France*

How Genetics, Cell Biology and Animal Models Informed
Our Understanding of Dystonia
William Dauer, *USA*

Dystonia as a Network Disorder: How Physiology and
Imaging Have Informed Our Understanding of Dystonia
Ryuji Kaji, *Japan*

The Mystery of Deep Brain Stimulation in Dystonia: Are We
Any Closer to Understanding How it Works?
Jill Ostrem, *USA*

CSPC Liaison: Carolyn Sue, *Australia*

At the conclusion of this session, participants should be better able to:

1. Discuss the role that advances in the basic sciences have played in our understanding of dystonia
2. Summarize the role that imaging and physiology have played in understanding the biological bases for dystonia
3. Analyze the current theories explaining the improvement of dystonia with Deep Brain Stimulation

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals,
Practitioners, Students/Residents/Trainees

3207 Parallel Session

Drug Repurposing in Parkinson's Disease

15:30 – 17:30

Chairs: Wassilios Meissner, *France*
D. James Surmeier, *USA*

Recent and Ongoing Clinical Trials with Repurposed Drugs
Michael Schwarzschild, *USA*

Repurposing Anti-Hypertensive Drugs: Rationale and
Clinical Experience
Tatyana Simuni, *USA*

Insulin Resistance and Diabetes: Repurposing Antidiabetics
as Disease Modifying Treatments
Wassilios Meissner, *France*

CSPC Liaison: Angela Cenci, *Sweden*

At the conclusion of this session, participants should be better able to:

1. Critically review recent clinical studies for Parkinson's disease involving inosine, nilotinib, simvastatin, and iron chelators
2. Summarize scientific rationale and clinical study of isradipine for disease modification in Parkinson's disease
3. Discuss the scientific rationale for repurposing antidiabetics as potential disease-modifying treatments for Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals,
Practitioners, Students/Residents/Trainees

3208 Science of Industry Session (non-CME)

See page 21 for complete session information.

3309 Teaching Course

Recognition and Management of Sleep Disturbances in Movement Disorders

15:30 – 17:30

Chairs: Ron Postuma, *Canada*
Aleksandar Videnovic, *USA*

Insomnia and Somnolence in Movement Disorders
Aleksandar Videnovic, *USA*

Restless Legs Syndrome in Movement Disorders
Juliane Winkelmann, *Germany*

Parasomnias and Sleep-Related Breathing Disorders in
Movement Disorders
Ron Postuma, *Canada*

CSPC Liaison: Wassilios Meissner, *France*

At the conclusion of this session, participants should be better able to:

1. Discuss the management of insomnia and excessive daytime sleepiness in movement disorders
2. Discuss the management of restless legs syndrome in movement disorders
3. Analyze investigations and therapeutic options for parasomnias and sleep-related breathing disorders in movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners,
Students/Residents/Trainees

Tuesday, September 24, 2019

3310 Teaching Course

Pediatric Movement Disorders

15:30 – 17:30

Chairs: Manju Kurian, *United Kingdom*
Ali Shalash, *Egypt*

Transient Benign Movement Disorders of Infancy
Emilio Fernández-Alvarez, *Spain*

Genetic Movement Disorders in Children and Adolescents
Manju Kurian, *United Kingdom*

Acquired Movement Disorders in Children and Adolescents
Darius Ebrahimi-Fakhari, *USA*

CSPC Liaison: Wassilios Meissner, *France*

At the conclusion of this session, participants should be better able to:

1. Recognize transient benign movement disorders in infancy
2. Summarize genetic movement disorders in children and adolescents
3. Illustrate acquired movement disorders in children and adolescents

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

3411 Skills Workshop

Allied Health Professionals' Skills for Proactive Patient Management

18:00 – 19:30

Terry Ellis, *USA*
Sue Thomas, *United Kingdom*

CSPC Liaison: Alice Nieuwboer, *Belgium*

In this interactive session, the presenters will focus on how to assess and manage Parkinson's disease patients proactively to maintain optimal levels of subjective well-being. The audience will learn about the benefits of involving nurses and physical therapists in patient care and learn about the timely interventions of each profession to prevent disease-related complications.

At the conclusion of this session, participants should be better able to:

1. Identify the most optimal management strategies to prevent Parkinson's disease-related complications in various disease stages
2. Define the role of the Parkinson's disease nurse in realizing proactive patient care
3. Explain methods to enhance exercise compliance and physical activity levels in Parkinson's disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3412 Skills Workshop

Clinical Applications of Big Data Analytics in Movement Disorders: Challenges, Promises and Potentials

18:00 – 19:30

Jean-Christophe Corvol, *France*
Charles Venuto, *USA*

CSPC Liaison: Roongroj Bhidayasiri, *Thailand*

In this session, the presenters will describe the nascent field of big data analytics in movement disorders, discuss the benefits as well as limitations, outline methodologies and applications on how to integrate small data sets. Examples with clinical applications will be provided (e.g. genetics and imaging). The presenters will briefly discuss challenges and offer recommendations for the future.

At the conclusion of this session, participants should be better able to:

1. Define advantages and challenges of big data analytics in movement disorders
2. Describe architectural framework of big data analytics through the process of application, development, and methodology
3. Evaluate examples of big data analytics in movement disorders (especially Parkinson's disease) with their clinical applications

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3413 Skills Workshop

Monogenic Hyperkinetic Disorders with Variable Phenotypes

18:00 – 19:30

Martin Paucar Arce, *Sweden*
Ana Westenberger, *Germany*

CSPC Liaison: Vincenzo Bonifati, *Netherlands*

In this interactive session, the presenters will describe the pleomorphic phenotypes associated with ATP1A3, ADCY5, and PDE10A and other related genes, as well as the underlying genotypes, and they will discuss how these rare monogenic movement disorders might provide insights for understanding normal brain functions and the pathogenesis of more common forms of complex movement disorders.

At the conclusion of this session, participants should be better able to:

1. Discuss disorders associated with mutations in the ATP1A3, ADCY5, and PDE10A gene variants
2. Illustrate the underlying genetic variants and emerging genotype-phenotype correlations
3. Discuss possible insights deriving from these rare monogenic forms for understanding of normal brain functions and the pathogenesis of more common movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Students/Residents/Trainees

Tuesday, September 24, 2019

3414 Skills Workshop

Eye Movements: A Case-Based Approach

18:00 – 19:30

Vivek Lal, USA

Aasef Shaikh, USA

CSPC Liaison: Roongroj Bhidayasiri, Thailand

In this interactive session, delegates will acquire clinical skills on how to examine ophthalmological, focusing on eye movement examinations, to recognize typical abnormalities and to integrate these findings into a differential diagnosis of movement disorder conditions.

At the conclusion of this session, participants should be better able to:

1. Describe the approach to a bedside neuro-ophthalmological exam in movement disorders
2. Recognize typical eye movement abnormalities in common hypokinetic and hyperkinetic disorders
3. Integrate findings from bedside ophthalmological examinations into differential diagnosis of movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3415 Skills Workshop

A Case-Based Approach for Management of Motor Fluctuations and Dyskinesias

18:00 – 19:30

Han-Joon Kim, South Korea

Fabrizio Stocchi, Italy

CSPC Liaison: Maria Stamelou, Greece

In this interactive session, the faculty will describe the clinical phenomenology of both motor fluctuations and dyskinesias in Parkinson's disease, along with current and potential future treatment strategies.

At the conclusion of this session, participants should be better able to:

1. Describe the various types of motor fluctuations in Parkinson's disease
2. Describe the various types of dyskinesias in Parkinson's disease
3. Summarize treatment strategies for motor fluctuation and dyskinesias

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3516 Video Session

Movement Disorder Emergencies

18:00 – 19:30

Roongroj Bhidayasiri, Thailand

Anna Castrioto, France

CSPC Liaison: Shen-Yang Lim, Malaysia

In this interactive session, the presenters will show videos of hypokinetic and hyperkinetic emergencies, and outline the management strategies for these conditions.

At the conclusion of this session, participants should be better able to:

1. Recognize clinical settings and signs of movement disorder emergencies, including emergencies related to Deep Brain Stimulation
2. Explain management strategies for the various Parkinson's disease related and other hypokinetic emergencies
3. Describe management strategies for the various hyperkinetic emergencies

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3617 Special Topics in Movement Disorders

Axial Movement Disorders: Camptocormia, Pisa Syndrome, Antecollis, and Retrocollis

18:00 – 19:30

Günther Deuschl, Germany

Michele Tinazzi, Italy

CSPC Liaison: Buz Jinnah, USA

In this session, faculty will describe axial defects in Parkinson's disease and other movement disorders including their clinical manifestations, pathophysiology and treatment.

At the conclusion of this session, participants should be better able to:

1. Describe the varied clinical manifestations of postural abnormalities in various movement disorders
2. Discuss possible mechanisms of postural problems in various movement disorders
3. Summarize avenues for management of postural problems in various movement disorders

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

3618 Special Topics in Movement Disorders

How to Become a Successful Movement Disorder Specialist

18:00 – 19:30

Yves Agid, France

Caroline Tanner, USA

CSPC Liaison: Roland Dominic Jamora, Philippines

In this interactive session, the presenters will discuss the approach to becoming a successful movement disorder specialist in academic and private practice settings.

At the conclusion of this session, participants should be better able to:

1. Recognize the best approach to becoming an excellent movement disorder specialist in academic medicine and in the clinic
2. Recognize the importance of searching for good mentors when pursuing specialization
3. Identify essential aspects of becoming an effective leader

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

Wednesday, September 25, 2019

4101 Plenary Session

Predicting Parkinson's Disease Onset and Progression

8:00 – 9:30

Chairs: Jean-Christophe Corvol, *France*
Matthew Stern, *USA*

What Can Big Cohorts Add to Prediction for Parkinson's Disease?

Andrew Siderowf, *USA*

Precision Medicine: Insights from Genetic and Other Biomarkers

Rejko Krueger, *Luxembourg*

Sleep and Parkinson's Disease: Prediction and Progression

Friederike Sixel-Doring, *Germany*

CSPC Liaison: Jean-Christophe Corvol, *France*

At the conclusion of this session, participants should be better able to:

1. Discuss implications of results from big cohorts in predicting onset or progression of Parkinson's disease
2. Discuss the role of genetic and other biomarkers in predicting onset or progression of Parkinson's disease
3. Identify the predictive value of sleep disorders in predicting onset or progression of Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4102 Plenary Session

Autoimmune Movement Disorders: From Phenomenology to Immunopathogenesis

10:00 - 12:00

Chairs: Jerome Honnorat, *France*
Carolyn Sue, *Australia*

How Do I Recognize an Autoimmune Movement Disorder?

Sarosh Irani, *United Kingdom*

The Pathogenesis of Autoimmune Movement Disorders

Angela Vincent, *United Kingdom*

Therapeutic Approaches to Autoimmune Movement Disorders

Sean Pittock, *USA*

CSPC Liaison: Carolyn Sue, *Australia*

At the conclusion of this session, participants should be better able to:

1. Describe the clinical clues for autoimmune movement disorders
2. Explain the molecular mechanisms of autoimmune movement disorders
3. Summarize therapeutic approaches for autoimmune movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4203 Parallel Session



TICKET

Placebos in Parkinson's Disease and Other Movement Disorders

15:00 – 17:00

Chairs: Christopher Goetz, *USA*
Olivier Rascol, *France*

The Science of Placebo

Fabrizio Benedetti, *Italy*

Assessing Placebo Response in Clinical Trials

Joaquim Ferreira, *Portugal*

Harnessing the Power of Placebos in Clinical Practice and Research

Tiago Mestre, *Canada*

CSPC Liaison: Jean-Christophe Corvol, *France*

At the conclusion of this session, participants should be better able to:

1. Discuss the scientific basis for the placebo response and related effects
2. Recognize the nature and underpinnings of the placebo and nocebo responses
3. Apply the novel perspectives on the use of placebos in research and clinical practice

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4204 Parallel Session



TICKET

Huntington's Disease: From Bench to Bedside

15:00 – 17:00

Chairs: Sandrine Humbert, *France*
Karen Marder, *USA*

The Many Presentations of Huntington's Disease and the Differential Diagnosis

Claudia Perandones, *Argentina*

The Role of Huntington in Neurodegeneration and Neurodevelopment: What Have We Learned?

Sandrine Humbert, *France*

Current and Future Therapies for Huntington's Disease

Sarah Tabrizi, *United Kingdom*

CSPC Liaisons: Emilia Gatto, *Argentina*

Karen Marder, *USA*

At the conclusion of this session, participants should be better able to:

1. Recognize the many variable phenotypes of Huntington's disease and potential differential diagnosis
2. Identify the genetic mechanisms underlying Huntington's disease
3. Identify the current and new therapies for Huntington's disease

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Wednesday, September 25, 2019

4205 Parallel Session

How to Diagnose Rare Movement Disorders

15:00 – 17:00

Chairs: Pedro Garcia Ruiz, *Spain*
Emilia Gatto, *Argentina*

Clinical Clues for Rare Movement Disorders
Pramod Pal, *India*

Laboratory Clues for Rare Movement Disorders
Emilia Gatto, *Argentina*

Neuroimaging Clues for Rare Movement Disorders
Pedro Garcia Ruiz, *Spain*

CSPC Liaison: Shen-Yang Lim, *Malaysia*

At the conclusion of this session, participants should be better able to:

1. Recognize clinical features of rare movement disorders
2. Discuss laboratory tests for rare movement disorders
3. Describe imaging findings of rare movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4206 Parallel Session

Spasticity: From Bench to Bedside

15:00 – 17:00

Chairs: Mark Hallett, *USA*
Raymond Rosales, *Philippines*

Recognition and Differential Diagnosis of Spasticity:
Hereditary and Acquired
Joerg Wissel, *Germany*

The Molecular and Physiological Basis for Spasticity
Craig Blackstone, *USA*

Recent Advances in the Management of Spasticity
Jean-Michel Gracies, *France*

CSPC Liaison: Buz Jinnah, *USA*

At the conclusion of this session, participants should be better able to:

1. Report the various clinical presentations and differential diagnosis of spasticity
2. Describe the biological basis for spasticity at the molecular and physiological levels
3. Summarize management options for spasticity

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4207 Parallel Session

Translating Genetic Discoveries into Disease-Modifying Strategies for Parkinson's Disease

15:00 – 17:00

Chairs: Alexis Brice, *France*
Carolyn Sue, *Australia*

Strategies Targeting Mitochondria
Carolyn Sue, *Australia*

Is LRRK2 Inhibition a Viable Disease-Modifying Strategy?
Mark Cookson, *USA*

Strategies for Disease-Modification Targeting GBA
Ziv Gan-Or, *Canada*

CSPC Liaison: Vincenzo Bonifati, *Netherlands*

At the conclusion of this session, participants should be better able to:

1. Compare the different strategies targeting mitochondria for Parkinson's disease
2. Discuss LRRK2 kinase inhibition as a strategy for Parkinson's disease
3. Compare the different strategies, targeting the glucocerebrosidase enzyme for Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

4208 Parallel Session

Dyskinesia in Parkinson's Disease: From the Bedside to the Lab Bench

15:00 – 17:00

Chair: Angelo Antonini, *Italy*
Philippe Damier, *France*

Update on the Clinical Phenomenology and Burden of Dyskinesias
Oscar Gershanik, *Argentina*

Modulation of Dopamine Signaling by Glutamate and Serotonin Receptors
Angela Cenci Nilsson, *Sweden*

Morphological and Functional Changes of Striatal and Cortical Neurons
Masahiko Tomiyama, *Japan*

CSPC Liaison: Angela Cenci, *Sweden*

At the conclusion of this session, participants should be better able to:

1. Review the incidence and clinical features of dyskinesias in Parkinson's disease, and their impact on activities of daily living
2. Appraise the mechanisms by which glutamate and serotonin receptors can modulate an altered dopamine signaling in dyskinesias
3. Summarize the evidence that dyskinesias relate to maladaptive changes of dendritic spines in striatal and cortical neurons

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Wednesday, September 25, 2019

4309 Teaching Course

Recognition and Management of Non-Motor Symptoms in Parkinson's Disease

15:00 – 17:00

Chairs: Bastiaan Bloem, *Netherlands*
K. Ray Chaudhuri, *United Kingdom*

Recognition and Management of Neuropsychiatric Disorders

Daniel Weintraub, *USA*

Recognition and Management of Dysautonomia

Alessandra Fanciulli, *Austria*

Recognition and Management of Pain and Fatigue

K. Ray Chaudhuri, *United Kingdom*

CSPC Liaison: Wassilios Meissner, *France*

At the conclusion of this session, participants should be better able to:

1. Describe the recognition and management of neuropsychiatric disorders in Parkinson's disease
2. Summarize the recognition and management of dysautonomia in Parkinson's disease
3. Discuss the recognition and management of pain and fatigue in Parkinson's disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4310 Teaching Course

Palliative Care for Parkinson's Disease

15:00 – 17:00

Chairs: Nicholas Galifianakis, *USA*
Victor McConvey, *Australia*

Definition and Models of Palliative Care

Stefan Lorenzl, *Germany*

Managing Palliative Needs of Patients and Their Caregivers

Nicholas Galifianakis, *USA*

End-of-Life Care

Miguel Coelho, *Portugal*

CSPC Liaison: Wassilios Meissner, *France*

At the conclusion of this session, participants should be better able to:

1. Define palliative care for Parkinson's disease
2. Manage palliative needs of patients with Parkinson's disease and their caregivers
3. Examine the management of end-of-life for Parkinson's disease

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4411 Skills Workshop

Practical Use of the MDS-UPDRS

17:30 – 19:00

Evžen Růžicka, *Czech Republic*

Glenn Stebbins, *USA*

CSPC Liaison: Christopher Goetz, *USA*

This interactive session will permit delegates to understand the core construct elements of the MDS-UPDRS, to practice application of the scale in a series of test cases, and to appreciate the process of establishing validated non-English editions. The session will be highly interactive between faculty and participants.

At the conclusion of this session, participants should be better able to:

1. Apply and interpret the scale in clinical and research settings
2. Practice using the MDS-UPDRS through interactive exercises and test cases during the session
3. Recognize the process utilized to develop validated non-English translations

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4412 Skills Workshop

Functional (Psychogenic) Movement Disorders

17:30 – 19:00

Isabel Parees, *Spain*

Jon Stone, *United Kingdom*

CSPC Liaison: Beomseok Jeon, *South Korea*

In this interactive session, the presenters will discuss how to effectively communicate about the diagnosis and management in patients with functional movement disorders. They will discuss novel/experimental treatments.

At the conclusion of this session, participants should be better able to:

1. Deliver an effective diagnostic explanation for functional movement disorders
2. Describe the approach for triaging patients for appropriate therapies
3. Interpret the nature of and role for novel/experimental treatments in functional movement disorders

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4413 Skills Workshop

Neuromodulation for Movement Disorders: A Case-Based Approach

17:30 – 19:00

Joohi Jimenez-Shahed, *USA*

Frank Steigerwald, *Germany*

CSPC Liaison: Elena Moro, *France*

In this interactive session, the audience will be involved in the discussion of the selection and treatment of difficult movement disorders cases with neuromodulation therapies. Participants will be able to recognize and learn how to manage several types of complications and side effects in patients treated with neuromodulation.

At the conclusion of this session, participants should be better able to:

1. Identify common and uncommon issues in neuromodulation therapies
2. Manage side effects and complications related to neuromodulation therapies
3. Summarize the rational steps to optimize neuromodulation therapies

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Wednesday, September 25, 2019

4414 Skills Workshop

Botulinum Toxins: Difficult Cases and Pitfalls

17:30 – 19:00

Austen Peter Moore, *United Kingdom*

Raymond Rosales, *Philippines*

CSPC Liaison: Roland Dominic Jamora, *Philippines*

This interactive session will present potential pitfalls in the treatment of movement disorders with botulinum toxins, along with management strategies for problems that are more difficult to treat.

At the conclusion of this session, participants should be better able to:

1. Recognize potential pitfalls in the application of botulinum toxins in clinical practice
2. Identify situations when botulinum toxin should not be used
3. Analyze strategies to manage difficult cases and improve outcome in botulinum toxin use

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

4515 Video Session

Lessons From My Patients

17:30 – 19:00

Francisco Cardoso, *Brazil*

Janet Rucker, *USA*

CSPC Liaisons: Shengdi Chen, *People's Republic of China*

Steven Frucht, *USA*

In this interactive session, experienced faculty will describe some of the important lessons they have learned from their patients. The discussion will focus on misleading presentations in some cases, the complexity of individualizing care, and the role that patients sometimes play in reaching a correct diagnosis or treatment strategy.

At the conclusion of this session, participants should be better able to:

1. Recognize unusual and sometimes misleading presentations of movement disorders
2. Discuss the complexity of delivering individualized patient care
3. Describe the role patients play in educating their physicians

Recommended Audience: Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4516 Video Session

Video Demonstration of Pediatric Movement Disorders

17:30 – 19:00

Miryam Carecchio, *Italy*

Rose Pons, *Greece*

CSPC Liaison: Maria Stamelou, *Greece*

In this interactive session, the presenters will demonstrate with illustrative videos the wide phenotypic spectrum of pediatric movement disorders and their evolution into adulthood. The audience will also observe video cases of potentially treatable pediatric movement disorders that are important not to miss.

At the conclusion of this session, participants should be better able to:

1. Describe the phenotypic spectrum of movement disorders in children
2. Recognize the evolution of pediatric movement disorders into adulthood
3. Determine potentially treatable pediatric movement disorders

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

4617 Special Topics in Movement Disorders

Sleep Disorders: REM Sleep Behavior Disorder

17:30 – 19:00

Michael Howell, *USA*

Michele Hu, *United Kingdom*

CSPC Liaison: Claudia Trenkwalder, *Germany*

In this interactive session the presenters will give insights into RBD symptoms, showing videos, defining the risk factors for prodromal Parkinson's disease and discussing the future role of RBD for clinical trials, focused on the problems of conversion from RBD.

At the conclusion of this session, participants should be better able to:

1. Identify the clinical symptomatology of RBD and its assessment
2. Illustrate the evolution of RBD into alpha-synucleinopathies
3. Define the role of RBD for potential therapeutic trials

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

4618 Special Topics in Movement Disorders

Normal Pressure Hydrocephalus for Movement Disorders Neurologists

17:30 – 19:00

Alfonso Fasano, *Canada*

Joachim Krauss, *Germany*

CSPC Liaison: Beomseok Jeon, *South Korea*

In this interactive session, the presenters will discuss clinical features, diagnostic tools, surgery and their limitations in diagnosing and managing normal pressure hydrocephalus.

At the conclusion of this session, participants should be better able to:

1. Describe the clinical features and tools useful for diagnosis and differential diagnosis of normal pressure hydrocephalus
2. Describe the heterogeneity and pathophysiological dilemmas of normal pressure hydrocephalus
3. Select and inform possible surgical candidates for shunting

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Thursday, September 26, 2019

5101 Themed Plenary Session

Synuclein in Parkinson's Disease and Atypical Parkinsonism: From Bench to Bedside

8:00 – 9:30

Chairs: Etienne Hirsch, *France*
Werner Poewe, *Austria*

Is Synucleinopathy a Single Entity?
Glenda Halliday, *Australia*

Pathogenic Spreading in the Synucleinopathies
Erwan Bezard, *France*

Clinical Trials in Synucleinopathies
Brit Mollenhauer, *Germany*

CSPC Liaison: Etienne Hirsch, *France*

At the conclusion of this session, participants should be better able to:

1. Analyze the clinical and pathological features of Parkinson's disease and atypical parkinsonism
2. Debate the role of α -synuclein in the initiation and progression of Parkinson's disease and atypical parkinsonism
3. Summarize new clinical trials for synucleinopathies

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

5102 Plenary Session

Controversies in Movement Disorders

10:00 – 11:00

Chairs: Oscar Gershanik, *Argentina*
Antonio Strafella, *Canada*

Is There a Role for Cannabinoids in Movement Disorders?
(YES)
Benzi Kluger, *USA*

Is There a Role for Cannabinoids in Movement Disorders?
(NO)
Janis Miyasaki, *Canada*

Early Deep Brain Stimulation in Parkinson's Disease?
(YES)
Patricia Limousin, *United Kingdom*

Early Deep Brain Stimulation in Parkinson's Disease?
(NO)
Beomseok Jeon, *South Korea*

CSPC Liaison: Antonio Strafella, *Canada*

At the conclusion of this session, participants should be better able to:

1. Debate the advantages and disadvantages of cannabinoids in movement disorders
2. Debate the advantages and disadvantages of early Deep Brain Stimulation in Parkinson's disease

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

5103 Plenary Session

Highlights for 2019: Looking Towards 2020

11:00 – 12:00

Chairs: Vincenzo Bonifati, *Netherlands*
Christopher Goetz, *USA*

Basic Sciences
Etienne Hirsch, *France*

Clinical Sciences
Claudia Trenkwalder, *Germany*

CSPC Liaisons: Vincenzo Bonifati, *Netherlands*
Claudia Trenkwalder, *Germany*

At the conclusion of this session, participants should be better able to:

1. Critically review high impact scientific discoveries from the past year and important areas of scientific focus for 2020 research
2. Critically review high impact clinical studies from the past year and important ongoing trials with anticipated completion in 2020

Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees

Non-CME Educational Activities

NEW! Science of Industry Session (non-CME)

These interactive sessions will provide delegates with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

Monday, September 23, 2019

2205	Science of Industry Session (non-CME)	TICKET
	Novel Treatment Strategies for Rare Movement Disorders	
	15:30 – 17:30	
Chairs:	David Devos, <i>France</i> Buz Jinnah, <i>USA</i>	
	PKAN: A Comparison of Multiple Potential Mechanisms and Treatment Strategies for Addressing the Biochemical Defect Thomas Klopstock, <i>Germany</i>	
	GLUT1: A Comparison of Treatment Strategies for Bypassing the Glucose Transporter Defect Emmanuel Roze, <i>France</i>	
	Reducing Brain Iron in Degenerative Disorders Massimo Pandolfo, <i>Belgium</i>	
CSPC Liaison: Buz Jinnah, <i>USA</i>		
At the conclusion of this session, participants should be better able to:		
<ol style="list-style-type: none"> 1. Describe the biological rationale for new drugs being developed to address the underlying biochemical defect in pantothenatekinase-associated neurodegeneration 2. Compare the biological basis and clinical outcomes for different treatment strategies being used for GLUT1-related disorders 3. Summarize the biological rationale and clinical outcomes for treatment strategies focusing on reducing brain iron in movement disorders 		
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees		

Tuesday, September 24, 2019

3208	Science of Industry Session (non-CME)	TICKET
	Translating Scientific Discovery into Novel Treatments for Movement Disorders	
	15:30 – 17:30	
Chairs:	Stanley Fahn, <i>USA</i> Buz Jinnah, <i>USA</i>	
	How Does Industry Decide Which Scientific Discoveries to Pursue? Jesse Cedarbaum, <i>USA</i>	
	Targeting LRRK2 for Parkinson's Disease Carole Ho, <i>USA</i>	
	The Biology of Pathological Oscillations in the Brain: Potential Novel Targets for Tremor Disorders? Margaret Lee, <i>USA</i>	
CSPC Liaison: Buz Jinnah, <i>USA</i>		
At the conclusion of this session, participants should be better able to:		
<ol style="list-style-type: none"> 1. Summarize the criteria used by industry to pursue clinical development of scientific discoveries 2. Describe the pathogenesis of LRRK2-related Parkinson's disease and its rationale as a therapeutic target 3. Describe how understanding the biological basis for neuronal oscillations points to novel therapeutics for tremor disorders 		
Recommended Audience: Basic scientists, Clinical academicians, Non-physician Health Professionals, Practitioners, Students/Residents/Trainees		

Faculty Listing

Tim Anderson, *New Zealand*
3102

Mathieu Anheim, *France*
3102

Angelo Antonini, *Italy*
1102, 4208

Selma Aybek Rusca, *Switzerland*
2208

Jean-Philippe Azulay, *France*
2102

Peter Bain, *United Kingdom*
3101

Fabrizio Benedetti, *Italy*
4203

Daniela Berg, *Germany*
1101

Erwan Bezard, *France*
5101

Kailash Bhatia, *United Kingdom*
3101

Roongroj Bhidayasiri, *Thailand*
3516

Craig Blackstone, *USA*
4206

Bastiaan Bloem, *Netherlands*
4309

Vincenzo Bonifati, *Netherlands*
3204, 5103

Alexis Brice, *France*
4207

Helen Bronte-Stewart, *USA*
2102

Francisco Cardoso, *Brazil*
4515

Miryam Carecchio, *Italy*
4516

Anna Castrioto, *France*
3516

Jesse Cedarbaum, *USA*
3208

M. Angela Cenci Nilsson, *Sweden*
4208

K. Ray Chaudhuri, *United Kingdom*
4309

Cynthia Comella, *USA*
2101

Maria Fiorella Contarino, *Netherlands*
2102

Mark Cookson, *USA*
4207

Jean-Christophe Corvol, *France*
3412, 4101

Esther Cubo Delgado, *Spain*
2616

Philippe Damier, *France*
4208

William Dauer, *USA*
3206

Marina De Koning-Tijssen, *Netherlands*
3205

Günther Deuschl, *Germany*
3617

David Devos, *France*
2205

Nico Diederich, *Luxembourg*
3203

Bruno Dubois, *France*
2203

Franck Durif, *France*
1101

Alexandra Durr, *France*
2206

Darius Ebrahimi-Fakhari, *USA*
3310

Mark Edwards, *United Kingdom*
2208

Carsten Eggers, *Germany*
2309

Rodger Elble, *USA*
3101

Terry Ellis, *USA*
3411

Stewart Factor, *USA*
MDS Video Challenge

Stanley Fahn, *USA*
3208

Alessandra Fanciulli, *Austria*
4309

Alfonso Fasano, *Canada*
4618

Gilles Fenelon, *France*
3203

Emilio Fernandez Alvarez, *Spain*
3310

Joaquim Ferreira, *Portugal*
4203

Susan Fox, *Canada*
1101

Jennifer Friedman, *USA*
2413

Steven Frucht, *USA*
3102, 3205

Nicholas Galifianakis, *USA*
4310

Ziv Gan-Or, *Canada*
4207

Christos Ganos, *Germany*
2207

Pedro Garcia Ruiz, *Spain*
4205

Emilia Gatto, *Argentina*
4205

Pierre Genton, *France*
3205

Oscar Gershanik, *Argentina*
4208, 5102

Nir Giladi, *Israel*
1102

Christopher Goetz, *USA*
2101, 4203, 5103

Lawrence Golbe, *USA*
2204

Jennifer Goldman, *USA*
1102, 2203

Mark Hallett, *USA*
4206

Glenda Halliday, *Australia*
5101

Clement Hamani, *Canada*
2102

Andreas Hartmann, *France*
2207

Rick Helmich, *Netherlands*
3101

Tove Henriksen, *Denmark*
2411

Etienne Hirsch, *France*
5101, 5103

Faculty Listing

Carole Ho, USA
3208

Jerome Honnorat, France
4102

Michael Howell, USA
4617

Michele Hu, United Kingdom
4617

Sandrine Humbert, France
4204

Sarosh Irani, United Kingdom
4102

Klaus Jahn, Germany
2617

Joseph Jankovic, USA
2515

Beomseok Jeon, South Korea
2208, 5102

Joohi Jimenez-Shahed, USA
4413

Hyder Jinnah, USA
2205, 3208

Ryuji Kaji, Japan
3206

Han-Joon Kim, South Korea
2310, 3415

Agnete Kirkeby, Denmark
2618

Christine Klein, Germany
2101, 4207

Thomas Klopstock, Germany
2205

Benzi Kluger, USA
5102

Joachim Krauss, Germany
4618

Rejko Krueger, Luxembourg
4101

Andrea Kuehn, Germany
2411

Manju Kurian, United Kingdom
3310, MDS Video Challenge

Kathrin LaFaver, USA
2208

Vivek Lal, USA
3414

Anthony Lang, Canada
MDS Video Challenge

Jee-Young Lee, South Korea
2310

Margaret Lee, USA
3208

Stephane Lehericy, France
2310

Simon Lewis, Australia
3203

Shen-Yang Lim, Malaysia
1101

Patricia Limousin, United Kingdom
5102

Irene Litvan, USA
1103, 2204

Stefan Lorenzl, Germany
4310

Elan Louis, USA
1104

Wim Mandemakers, Netherlands
2618

Karen Marder, USA
4204

Laura Marsh, USA
3203

Davide Martino, Canada
2207

Victor McConvey, Australia
4310

Wassilios Meissner, France
3207

Niccolo Mencacci, USA
3204

Aurelie Meneret, France
3204

Tiago Mestre, Canada
4203, MDS Video Challenge

Janis Miyasaki, Canada
5102

Hidehiro Mizusawa, Japan
2206

Brit Mollenhauer, Germany
5101

Austen Moore, United Kingdom
4414

Francesca Morgante, United Kingdom
MDS Video Challenge

Elena Moro, France
1102

Huw Morris, United Kingdom
2204

Alice Nieuwboer, Belgium
2309

Jorik Nonnekes, Netherlands
2617

Jill Ostrem, USA
3206

Pramod Pal, India
4205

Stéphane Palfi, France
2102

Massimo Pandolfo, Belgium
2205

Isabel Parees, Spain
4412

Martin Paucar Arce, Sweden
3413, MDS Video Challenge

Maria Teresa Pellecchia, Italy
1103

Claudia Perandones, Argentina
4204

Maria Elisa Piemonte, Brazil
2309

Sean Pittock, USA
4102

Werner Poewe, Austria
5101

Rose Pons, Greece
4516

Ron Postuma, Canada
3309

Olivier Rascol, France
1101, 4203

Stephen Reich, USA
2204

Irena Rektorova, Czech Republic
2203

Gesine Respondek, Germany
2514

Mayela Rodriguez Violante, Mexico
2309, 2413

Faculty Listing

Raymond Rosales, *Philippines*
4206, 4414

Emmanuel Roze, *France*
2205

Janet Rucker, *USA*
4515

Evžen Růžicka, *Czech Republic*
4411

Ludger Schöels, *Germany*
2206

Michael Schwarzschild, *USA*
3207

Kapil Sethi, *USA*
MDS Video Challenge

Aasef Shaikh, *USA*
3414

Ali Shalash, *Egypt*
2616, 3310

Huifang Shang, *People's Republic of China*
2412

Hiroshi Shibasaki, *Japan*
3205

Andrew Siderowf, *USA*
4101

Tatyana Simuni, *USA*
3207

Friederike Sixel-Doring, *Germany*
4101

Elizabeth Slow, *Canada*
1104

Maria Stamelou, *Greece*
2204, 3101

Iva Stankovic, *Serbia*
2514

Glenn Stebbins, *USA*
4411

Frank Steigerwald, *Germany*
4413

Matthew Stern, *USA*
4101

Fabrizio Stocchi, *Italy*
3415

Jon Stone, *United Kingdom*
4412

Antonio Strafella, *Canada*
1104, 2203, 5102

Carolyn Sue, *Australia*
4102, 4207

D. James Surmeier, *USA*
3207

Matthis Synofzik, *Germany*
2412

Sarah Tabrizi, *United Kingdom*
4204

Louis Tan, *Singapore*
1102

Caroline Tanner, *USA*
3618

Helio Teive, *Brazil*
2206

Sue Thomas, *United Kingdom*
3411

Michele Tinazzi, *Italy*
3617

Francois Tison, *France*
1103

Masahiko Tomiyama, *Japan*
4208

Christine Tranchant, *France*
1104

Claudia Trenkwalder, *Germany*
2101, 5103

Enza Valente, *Italy*
3204

Martje Van Egmond, *Netherlands*
3205

Thilo Van Eimeren, *Germany*
2310

Charles Venuto, *USA*
3412

Marie Vidailhet, *France*
1104, 3206

Aleksandar Videnovic, *USA*
3309

Angela Vincent, *United Kingdom*
4102

Daniel Weintraub, *USA*
4309

Gregor Wenning, *Austria*
1103

Ana Westenberger, *Germany*
3413

Caroline Williams-Gray, *United Kingdom*
2203

Juliane Winkelmann, *Germany*
3309

Joerg Wissel, *Germany*
4206

Yulia Worbe, *France*
2207

CME Information

Target Audience

Clinicians, researchers, post-doctoral fellows, medical residents, medical students, allied health professionals with an interest in current clinical trends and approaches for diagnosis and treatment of movement disorders.

Objectives

- 1) Evaluate the pharmacological and non-pharmacological management options available for Parkinson's disease and other movement disorders
- 2) Discuss the diagnostic approaches and tools available for Parkinson's disease and other movement disorders
- 3) Describe the pathogenesis and neurobiology of Parkinson's disease and other movement disorders

Satisfactory Completion

Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

Accreditation Statement

The International Parkinson and Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

Credit Designation Statement

The International Parkinson and Movement Disorder Society designates this live activity for a maximum of 33.0 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Acknowledgements

Platinum Plus Level

abbvie

Bial
Keeping life
in mind.

Zambon
1906

Platinum Level

ACORDA[®]
THERAPEUTICS

 **Biogen**[®]

**Boston
Scientific**

 **BRITANNIA**
PHARMACEUTICALS LTD

Medtronic

 **Roche**

 **SUNOVION**

Bronze Level


Ipsen Innovation

The International Congress of Parkinson's Disease and Movement Disorders Scientific Program is supported through an unrestricted medical education grant from Ipsen Innovation.

Exablate Neuro

INCISIONLESS, MR-GUIDED FOCUSED ULTRASOUND THALAMOTOMY FOR ESSENTIAL TREMOR & TREMOR-DOMINANT PARKINSON'S DISEASE

- Immediate improvement in tremor¹
- Sub-millimeter target movement
- Real-time, physiologic feedback to optimize treatment
- Safe & effective with minimal side effects¹



INSIGHTEC

www.insightec.com | www.essential-tremor.com

¹Elias WJ, Lipsman N, Ondo WG, Ghanouni P, Kim YG, Lee W, Schwartz M, Hynynen K, Lozano AM, Shah B, Huss D, Dallapiazza RF, Gwinn R, Witt J, Ro S, Eisenberg HM, Fishman PS, Gandhi D, Halpern CH, Chuang R, Butts Pauly K, Tierney TS, Hayes MT, Cosgrove GR, Yamaguchi T, Abe K, Taira T, Chang JW. An International, Randomized, Controlled Trial of Focused Ultrasound Thalamotomy for Essential Tremor. The New England Journal of Medicine, Aug 2016.

Safety Information: <https://www.insightec.com/us/safety-information>

Product Name: Exablate Neuro PUB41003838 Rev. 1

VERCISE™

Deep Brain Stimulation System

GUIDE XT VISUALIZATION EMPOWERED



GUIDE XT is DBS Visualization Software that provides the ability to see implanted leads and Stimulation Field Models (SFMs) in the patient's own segmented anatomy.

All cited trademarks are the property of their respective owners.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority registrations.

Material not intended for use in France .

Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service. Guide XT is intended to display medical images and simulate stimulation output. It includes functions for image manipulation and 3D visualization (reconstructions and volume rendering). Features include the display of a simulated DBS lead from a patient's CT scan compared to an anatomical atlas. The Vercise™ Deep Brain Stimulation (DBS) Systems are indicated for use in unilateral or bilateral stimulation of the subthalamic nucleus (STN) or internal globus pallidus (GPi) for treatment of levodopa-responsive Parkinson's disease which is not adequately controlled with medication and also for treatment of intractable primary and secondary Dystonia, for persons 7 years of age and older.

Thalamic stimulation using the Boston Scientific Vercise™ DBS Systems is indicated for the suppression of tremor not adequately controlled by medications in patients diagnosed with Essential Tremor or Parkinson's disease.


NM-562807-AA © 2018 Boston Scientific Corporation or its affiliates. All rights reserved.

MAKE A **PARKINSON'S HOUSE CALL**

Visit the Sunovion Booth

for an immersive and interactive exhibit that illustrates life with Parkinson's disease and the types of OFF episodes that patients experience.



LITTLE BIG THINGS is a trademark of Sunovion Pharmaceuticals Inc.
SUNOVION and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marlborough, MA 01752
©2019 Sunovion Pharmaceuticals Inc. All rights reserved. 03/19 NPC-APL-US-00045-19

TAKE YOUR PATIENTS ON A SMARTER DBS JOURNEY

Unleash your DBS programming potential with the intuitive, insightful, secure **Clinician Programmer.**



Our clinician programmer makes a smarter journey possible with next-generation programming technology designed to build trust and confidence. With an intuitive interface, secure wireless connection, and streamlined access to patient data—you'll have all the support you need along the way.

**Visit our booth to learn more about
the DBS Clinician Programmer.**

medtronic.com/dbstherapy

A prescription is required. Not everyone who receives DBS Therapy will receive the same results. DBS Therapy requires brain surgery which can have serious and sometimes fatal complications. Once implanted, DBS complications may require additional surgery. Medtronic DBS Therapy may cause new or worsening neurological or psychiatric symptoms. Patients should always discuss the potential risks and benefits of the therapy with a physician.

©2018 Medtronic UC201901991a EN

Medtronic
Further, Together

Biogen invites you to join an engaging panel discussion on progressive supranuclear palsy (PSP).

A stylized illustration of a human brain in shades of green. The brain is shown from a side profile, with the cerebral cortex and gyri clearly defined by black outlines. The background is a light green gradient. The brain is positioned in the upper right quadrant of the image, with its base extending towards the bottom right.

Differentiating PSP

Monday, September 23, 2019

12:45 PM–1:45 PM

Nice Acropolis Convention Centre

Nice, France

Bial

Keeping life
in mind.

A symposium at the International
Congress of Parkinson's Disease
and Movement Disorders, Nice, France

BEYOND MOTOR WEARING-OFF: WHAT ARE WE MISSING?

AGENDA

Professor Olivier Rascol
TOULOUSE, FRANCE
Chairman's introduction

Professor Hubert Fernandez
CLEVELAND, USA
The spectrum of OFF

Professor Per Odin
LUND, SWEDEN
The time course of
non-motor complications

Professor Joaquim Ferreira
LISBON, PORTUGAL
The time course of
motor complications

Panel discussion

Lunch bags available for symposium attendees

Monday
23 September 2019
12:45-13:45

Les Muses 1,
Nice Acropolis
Convention Centre

This symposium is organised and fully sponsored by BIAL
ON/JUL19/G/239 Date of preparation: July 2019



International Parkinson and
Movement Disorder Society

**International Congress of Parkinson's
Disease and Movement Disorders®**

NICE, FRANCE SEPTEMBER 22-26, 2019

Preliminary Program